Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palbociclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 20/20 | 1.00 |
| ▸ | CCND1 known ✓ | P24385 | 16/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 5/20 | 0.98 |
| ▸ | CCND3 | P30281 | 13/20 | 0.98 |
| ▸ | CCND2 | P30279 | 12/20 | 0.98 |
| ▸ | CDK2 | P24941 | 5/20 | 0.98 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.98 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.98 |
| ▸ | CDK9 | P50750 | 2/20 | 0.98 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.98 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.98 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.98 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.98 |
| ▸ | STK16 | O75716 | 1/20 | 0.98 |
| ▸ | CCNK | O75909 | 1/20 | 0.98 |
| ▸ | PDE5A | O76074 | 1/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.98 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palbociclib SCHEMBL2076416 | 1.00 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29387795 | 1.00 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29379411 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL30584526 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL462630 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29362383 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Hydrochloric Acid SCHEMBL4828453 | 0.98 | CDK4 (0.98) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL28567292 | 0.98 | CDK4 (0.97) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL4827183 | 0.97 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL30176561 | 0.97 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120189510-A | Application of fused ring compound | 北京哲源科技有限责任公司 | 2025-06-24 | — | — | CN | claimed |
| CN-117899085-A | Pharmaceutical composition and pharmaceutical preparation for improving success rate of full-thickness skin grafting and application thereof | 无锡市南京大学锡山应用生物技术研究所 | 2024-04-19 | — | — | CN | claimed |
| CN-114181905-B | Exosome easy to penetrate blood brain barrier | 南京中医药大学 | 2024-03-22 | — | — | CN | claimed |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | BROWN UNIVERSITY | 2023-06-15 | — | — | US | claimed |
| CN-115721724-A | Pharmaceutical composition containing secondary amine compound and preparation and application thereof | 山东威智中科药业有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-114181905-A | Exosome easy to permeate blood brain barrier | 南京中医药大学 | 2022-03-15 | — | — | CN | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4729940-A2 | LARGE SCALE ORGANOID ANALYSIS | Tempus AI, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4070098-B1 | LARGE SCALE ORGANOID ANALYSIS | TEMPUS AI INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250250540-A1 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250243456-A1 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2022258001-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | 上海岸阔医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20220323406-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-10-13 | — | — | US | disclosed |
| CN-108017630-B | Preparation method of small-specific-surface-area palbociclib free base | 上海创诺制药有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220280519-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| US-11332467-B2 | Solid state forms of palbociclib dimesylate | PLANTEX LTD. (IL) | 2022-05-17 | — | — | US | disclosed |
| CN-114181905-A | Exosome easy to permeate blood brain barrier | 南京中医药大学 | 2022-03-15 | — | — | CN | disclosed |
| CN-109729716-B | PI3K inhibitor combination | 拜耳制药股份公司 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332467-B2 | Solid state forms of palbociclib dimesylate | CDK4, SETD1B, CDK3 | CDK4 1/4885CCND1 171/4885CDK6 7/4885 |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | PAX2, ZP1, ALDH1A2 | CDK4 2982/4885CCND1 2299/4885CDK6 3800/4885 |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | CHI3L1, CHI3L2, ACE2 | CDK4 4545/4885CCND1 4876/4885CDK6 4683/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | CDK4 298/4885CCND1 3763/4885CDK6 640/4885 |
| US-20220280519-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | MCL1, MPL, BCL9 | CDK4 93/4885CCND1 544/4885CDK6 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.